Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 12, 2015, Pages 1759-1767

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Kajiwara, Eiji ^b   Nomura, Hideyuki ^c   Kawano, Akira ^d   Takahashi, Kazuhiro ^e   Dohmen, Kazufumi ^f   Satoh, Takeaki ^g   Azuma, Koichi ^h   Nakamuta, Makoto ⁱ   Koyanagi, Toshimasa ^j   Kotoh, Kazuhiro ^k   Shimoda, Shinji ^k   Hayashi, Jun ^l  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^c Shin Kokura Hospital   (Japan)

^d KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^e HAMANOMACHI HOSPITAL   (Japan)

^f CHIHAYA HOSPITAL   (Japan)

^g Kokura Medical Center   (Japan)

^h Kyushu Central Hospital   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION   (Japan)

^j Fukuoka City Hospital   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l Hara Doi Hospital   (Japan)

more..

Author keywords

Adverse effect; Hepatitis C virus; Pegylated interferon; Simeprevir; Telaprevir

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

AGED; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHARMACOGENETICS; PROPENSITY SCORE; STATISTICAL MODEL; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PHARMACOGENETICS; POLYETHYLENE GLYCOLS; PROPENSITY SCORE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; SIMEPREVIR; TREATMENT OUTCOME;

EID: 84954416907     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13016     Document Type: Article

References (30)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014; 146: 1145-50.
3. Morgan TR, Ghany MG, Kim HY et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.
4. Ogawa E, Furusyo N, Kajiwara E et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study. J. Hepatol. 2013; 58: 495-501.
5. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 23: 2405-16.
6. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 23: 2417-28.
7. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-17.
8. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 31: 1195-206.
9. Furusyo N, Ogawa E, Nakamuta M et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J. Hepatol. 2013; 59: 205-12.
10. Rosenquist Å, Samuelsson B, Johansson PO et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 2014; 57: 1673-93.
11. Zeuzem S, Berg T, Gane E et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.
12. Manns M, Marcellin P, Poordad F et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-26.
13. Forns X, Lawitz E, Zeuzem S et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.
14. Kumar S, Jacobson IM. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. J. Hepatol. 2014; 61: S91-7.
15. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment. Pharmacol. Ther. 2014; 39: 478-87.
16. Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
17. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
18. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
19. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
20. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59: 46-8.
21. Ogawa E, Furusyo N, Nakamuta M et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J. Hepatol. 2013; 59: 667-74.
22. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am. J. Epidemiol. 1999; 150: 327-33.
23. Ogawa E, Furusyo N, Nakamuta M et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment. Pharmacol. Ther. 2013; 38: 1076-85.
24. Furusyo N, Ogawa E, Sudoh M et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J. Hepatol. 2012; 57: 1186-92.
25. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013; 3: 1878-87.
26. Kowdley KV, Lawitz E, Crespo I et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-7.
27. Huisman MT, Snoeys J, Monbaliu J et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010; 52: 461A.
28. Reddy KR, Zeuzem S, Zoulim F et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect. Dis. 2015; 15: 27-35.
29. Vera-Llonch M, Martin M, Aggarwal J et al. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment. Pharmacol. Ther. 2013; 38: 124-33.
30. Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014; 59: 46-8.